Search Results - "Roberto Zajdenverg"

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials by Eron, Joseph J, Prof, Young, Benjamin, MD, Cooper, David A, Prof, Youle, Michael, MD, DeJesus, Edwin, MD, Andrade-Villanueva, Jaime, MD, Workman, Cassy, MD, Zajdenverg, Roberto, MD, Fätkenheuer, Gerd, Prof, Berger, Daniel S, MD, Kumar, Princy N, MD, Rodgers, Anthony J, MS, Shaughnessy, Melissa A, MS, Walker, Monica L, BS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Xu, Xia, PhD, Sklar, Peter, Dr

“…Summary Background To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might…”
Get full text

Improving the continuum of care monitoring in Brazilian HIV healthcare services: An implementation science approach by Loch, Ana Paula, Rocha, Simone Queiroz, Fonsi, Mylva, de Magalhães Caraciolo, Joselita Maria, Kalichman, Artur Olhovetchi, de Alencar Souza, Rosa, Gianna, Maria Clara, Gonçalves, Alexandre, Short, Duncan, Pimenta, Shenia Liane, Bagnola, Lea, Wonhnrath Menuzzo, Carolina, da Rocha Meireles, Zulmira, Natividade Diz, Eunice, Zajdenverg, Roberto, Prudente, Isidoro, Battistella Nemes, Maria Ines

“…To evaluate the impact of an intervention improving the continuum of care monitoring (CCM) within HIV public healthcare services in São Paulo, Brazil, and…”
Get full text

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO) by Wyk, Jean Van, Ajana, Faïza, Bisshop, Fiona, de Wit, Stéphane, Ait‐Khaled, Mounir, Wang, Ruolan, Wright, Jonathan, Aboud, Michael, Smith, Kimberly, Zajdenverg, Roberto

Get full text

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial by Cooper, David A, Cordery, Damien V, Zajdenverg, Roberto, Ruxrungtham, Kiat, Arastéh, Keikawus, Bergmann, Frank, Neto, José L de Andrade, Scherer, Joseph, Chaves, Ricardo L, Robinson, Patrick

“…Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance…”
Get full text

ANÁLISE DE SUBGRUPO DOS RESULTADOS DE EFICÁCIA E SEGURANÇA DA SEMANA 96 AVALIANDO O FOSTEMSAVIR EM PARTICIPANTES INFECTADOS POR HIV‐1 EXTENSAMENTE EXPERIMENTADOS AO TRATAMENTO NO ESTUDO DE FASE 3 BRIGHTE: RESULTADOS DA COORTE RANDOMIZADA by Ackerman, Peter, Aberg, Judith, Molina, Jean‐Michael, Cassetti, Isabel, Kozal, Michael, Treviño‐Pérez, Sandra, Streinu‐Cercel, Adrian, Latiff, Gulam, Zajdenverg, Roberto, Sprinz, Eduardo

Get full text

Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil by Merçon, Monica, Tuboi, Suely H, Batista, Sônia Maria, Telles, Sandra Regina Barros, Grangeiro, José Roberto, Zajdenverg, Roberto, Lago, Regina Ferro do, Barroso, Paulo Feijó, Melo, Maria de Fátima, Schechter, Mauro

“…This study investigated the risk factors associated with recent and chronic HIV infections among individual attending a voluntary counseling and testing (VCT)…”
Get full text

Efficacy and safety of DTG plus 3TC for prophylaxis of perinatal transmission of HIV infection in pregnant women who have detectable viral load after 14 weeks of gestation: A pilot study (PREGNANCY) by Brites, Carlos, Luz, Estela, Nóbrega, Isabella, Luz, Ivana, Zajdenverg, Roberto, de Ruiter, Annemiek, Jones, Bryn, Lorenzo, Cynthia R, Travassos, Ana Gabriela

“…Abstract Background The prevention of perinatal HIV transmission depends on the safe and effective use of antiretroviral therapy (ART). Simplifying treatment…”
Get full text

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI by Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Jörg Sievers, Choy Man, Rimgaile Urbaityte, Mark Underwood, Jean Andre Van Wyk, Kimberly Smith, Roberto Zajdenverg

Get full text

CARACTERIZAÇÃO DE PESSOAS VIVENDO COM HIV/AIDS EM FALHA TERAPÊUTICA ATENDIDAS NO SISTEMA ÚNICO DE SAÚDE by Ana Paula Loch, Myva Fonsi, Simone Queiroz Rocha, Joselita Maria de M. Caraciolo, Rosa de Alencar Souza, Maria Clara Gianna, Duncan Short, Roberto Zajdenverg, Isidoro Prudente, Maria Ines Batt Nemes

Get full text

Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts by Schechter, Mauro, Zajdenverg, Roberto, Falco, Gisely, Barnes, Grace Link, Faulhaber, Jose Claudio, Coberly, Jacqueline S, Moore, Richard D, Chaisson, Richard E

“…Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies. To compare…”
Get full text

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults by CARR, Andrew, RITZHAUPT, Armin, WEI ZHANG, ZAJDENVERG, Roberto, WORKMAN, Cassy, GATELL, Jose M, CAHN, Pedro, CHAVES, Ricardo

“…Thymidine-based nucleoside analogue reverse transcriptase inhibitors and some protease inhibitors of HIV are associated with lipoatrophy, relative central fat…”
Get full text

Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks by ZAJDENVERG, Roberto, PODSADECKI, Thomas J, BADAL-FAESEN, Sharlaa, ANDRADE-VILLANUEVA, Jaime, GATHE, Joseph, MINGRONE, Horacio, FREDRICK, Linda M, GAULTIER, Isabelle A, WOODWARD, W. Chris, BERNSTEIN, Barry M

“…To compare the safety and antiviral activity of once (QD) or twice (BID) daily lopinavir/ritonavir (LPV/r) in combination with investigator-selected…”
Get full text

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI by Cahn, Pedro, Madero, Juan Sierra, Arribas, José Ramón, Sievers, Jörg, Man, Choy, Urbaityte, Rimgaile, Underwood, Mark, Wyk, Jean Andre Van, Smith, Kimberly, Zajdenverg, Roberto

Get full text

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO) by Wyk, Jean Van, Ajana, Faïza, Bisshop, Fiona, de Wit, Stéphane, Ait‐Khaled, Mounir, Wang, Ruolan, Wright, Jonathan, Aboud, Michael, Smith, Kimberly, Zajdenverg, Roberto

Get full text

Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil by Sprinz, Eduardo, Netto, Eduardo M, Patelli, Maria, Lima, J S, Lima, Maria Patelli J S, Furtado, Juvênao J D, da Eira, Margareth, Zajdenverg, Roberto, Madruga, José V, Lewi, David S, Machado, Alcyone A, Pedro, Rogério J, Soares, Marcelo A

“…Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) has been documented in all countries that have surveyed for it and may result in an…”
Get more information

CARACTERIZAÇÃO DE PESSOAS VIVENDO COM HIV/AIDS EM FALHA TERAPÊUTICA ATENDIDAS NO SISTEMA ÚNICO DE SAÚDE by Loch, Ana Paula, Fonsi, Myva, Rocha, Simone Queiroz, Caraciolo, Joselita Maria de M., Souza, Rosa de Alencar, Gianna, Maria Clara, Short, Duncan, Zajdenverg, Roberto, Prudente, Isidoro, Nemes, Maria Ines Batt

Get full text

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naive HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial: e0144917 by Cooper, David A, Cordery, Damien V, Zajdenverg, Roberto, Ruxrungtham, Kiat, Arasteh, Keikawus, Bergmann, Frank, Neto, L deAndrade, Scherer, Joseph, Chaves, Ricardo L, Robinson, Patrick

“…Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naive HIV-1-infected patients because of its potency, unique resistance…”
Get full text

Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy by Bucciardini, Raffaella, Fragola, Vincenzo, Massella, Maurizio, Polizzi, Cosimo, Mirra, Marco, Goodall, Ruth, Carey, Dianne, Hudson, Fleur, Zajdenverg, Roberto, Floridia, Marco

“…The health-related quality of life (HRQoL) outcomes in HIV-infected, treatment-naive patients starting different HAART regimens in a 3-year, randomized,…”
Get more information

SEGURANÇA E EFICÁCIA DA TERAPIA ANTIRRETROVIRAL BASEADA EM DOLUTEGRAVIR, NA SEMANA 48, EM ADULTOS COINFECTADOS HIV/TB by Dooley, Kelly E., Kaplan, Richard, Mwelase, Noluthando, Grinsztejn, Beatriz, Ticona, Eduardo, Lacerda, Marcus, Sued, Omar, Belonosova, Elena, Ait‐Khaled, Mounir, Angelis, Kostas, Brown, Dannae, Singh, Rajendra, Talarico, Christine, Tenorio, Allan, Keegan, Michael, Aboud, Michael, Zajdenverg, Roberto

Get full text

NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LAMIVUDIDINA (3 TC) VERSUS DTG MAIS DOSE FIXA COMBINADA DE TENOFOVIR/EMTRICITABINA (TDF/FTC) EM ADULTOS VIRGENS DE TRATAMENTO ANTIRRETROVIRAL QUE VIVEM COM HIV‐1: RESULTADOS DE 48 SEMANAS DOS ESTU by Cahn, Pedro, Sierra‐Madero, Juan, Arribas, Jose, Antinori, Andrea, Ortiz, Roberto, Clarke, Amanda, Hung, Chien‐Ching, Rockstroh, Juergen, Girard, Pierre‐Marie, Man, Choy, Sievers, Jorg, Currie, Alexander, Underwood, Mark, Tenorio, Allan, Pappa, Keith, Wynne, Brian, Gartland, Martin, Aboud, Michael, Smith, Kimberly, Zajdenverg, Roberto

Get full text